BioVie Inc. (BIVI) shareholders
Close on Nov 17, 2026Market cap $7.51MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Terren S. Peizer Joint filing with Acuitas Group Holdings, LLC (15.80%) | 3,050,394 | 15.80% | 13D (active) amendment | Jun 25, 2025 |
| Morgan Stanley Smith Barney LLC Joint filing with Morgan Stanley (11.90%) | 896,822 | 11.90% | 13G (passive) amendment | Jul 31, 2026 |
| Alta Partners LLC | 687,321 | 8.40% | 13G (passive) | Aug 12, 2026 |
| Do Cuong V Joint filing with Do & Rickles Investments, LLC (5.02%) | 399,018 | 5.03% | 13D (active) | Jan 5, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BIVI | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Morgan Stanley | 605,471 | – | $1.17M | +530,250 | 0.00% |
| Diametric Capital, LP | 256,636 | – | $497.87K | −113,364 | 0.05% |
| Renaissance Technologies LLC | 127,918 | – | $248.16K | +60,000 | 0.00% |
| Citadel Advisors LLC | 95,952 | – | $186.15K | +50,660 | 0.00% |
| Vanguard Capital Management LLC | 70,906 | – | $137.56K | −13,161 | 0.00% |
| Geode Capital Management, LLC | 70,752 | – | $137.26K | −13,451 | 0.00% |
| Philadelphia Trust Co | 50,010 | – | $97.00K | −25,000 | 0.01% |
| Vanguard Fiduciary Trust Co | 37,557 | – | $72.86K | – | 0.00% |
| Jane Street Group, LLC | 35,860 | – | $69.57K | +13,069 | 0.00% |
| Prelude Capital Management, LLC | 32,583 | – | $63.21K | −59,480 | 0.00% |
| Cambridge Investment Research Advisors, Inc. | 27,632 | – | $54.00K | New | 0.00% |
| Northern Trust Corp | 21,820 | – | $42.33K | +7,631 | 0.00% |
| Persistent Asset Partners Ltd | 14,996 | – | $29.09K | New | 0.01% |
| XTX Topco Ltd | 14,228 | – | $27.60K | −6,998 | 0.00% |
| Caprock Group, LLC | 11,300 | – | $21.92K | New | 0.00% |
| Allworth Financial LP | 5,600 | – | $10.86K | – | 0.00% |
| UBS Group AG | 2,175 | – | $4.22K | +2,169 | 0.00% |
| Tower Research Capital LLC (TRC) | 2,064 | – | $4.00K | −5,476 | 0.00% |
| PNC Financial Services Group, Inc. | 1,000 | – | $1.94K | – | 0.00% |
| SBI Securities Co., Ltd. | 867 | – | $1.68K | +636 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 36 | 1M | 6 / 8 | 11 / 3 | 1M | 0M |
| Q1 2026 | 33 | 1M | 7 / 7 | 5 / 7 | 0M | 0M |
| Q4 2025 | 35 | 1M | 7 / 5 | 10 / 4 | 0M | 0M |
| Q3 2025 | 32 | 1M | 31 / 1 | 0 / 0 | 1M | 0M |
| Q2 2025 | 1 | 0M | 1 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
6 funds held BIVI in Q2 2026, 51% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of BIVI | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 70,906 | – | $137.56K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 55,453 | – | $78.74K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 10,898 | – | $15.48K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 2,401 | – | $3.41K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 230 | – | $327 | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 10 | – | $19 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Cuong V. Do | President & CEO, Director | 28,609 | Nov 16, 2026 |
| Joseph M. Palumbo | Chief Medical Officer | 6,036 | Aug 28, 2026 |
| Joanne Wendy Kim | Chief Financial Officer | 3,441 | Aug 28, 2026 |
| Amy Suzon Chappell | Director | 727 | Aug 28, 2026 |
| Sigmund Rogich | Director | 36,926 | Jan 9, 2026 |
| Kameel D. Farag | Director | – | Jan 9, 2026 |
| James Paul Lang | Director | 68,622 | Jan 9, 2026 |
| Michael Edward Sherman | Director | 20,679 | Jan 9, 2026 |
| Robert J. Hariri | Director | 42,254 | Jan 7, 2025 |
| Richard J. Berman | Director | 40,643 | Jan 7, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Cuong V. Do President & CEO, Director | Nov 13, 2026 | Buy | +2,500 | $1.16 | $2.91K | 18,617 |
| Amy Suzon Chappell Director | Aug 28, 2026 | Buy | +727 | $2.16 | $1.57K | 727 |
| Joseph M. Palumbo Chief Medical Officer | Aug 28, 2026 | Buy | +4,843 | $2.16 | $10.46K | 6,036 |
| Joanne Wendy Kim Chief Financial Officer | Aug 28, 2026 | Buy | +2,500 | $2.18 | $5.45K | 3,441 |
| Cuong V. Do President & CEO, Director | Aug 27, 2026 | Buy | +15,210 | $2.08 | $31.64K | 16,117 |
| Cuong V. Do President & CEO, Director | Aug 7, 2025 | Buy | +5,000 | – | – | 9,992 |
| Sigmund Rogich Director | Nov 20, 2024 | Award | +32,700 | – | – | 36,926 |
| Richard J. Berman Director | Nov 20, 2024 | Award | +34,200 | – | – | 40,643 |
| Joanne Wendy Kim Chief Financial Officer | Jun 24, 2024 | Award | +73,000 | – | – | 112,196 |
| Joanne Wendy Kim Chief Financial Officer | Jun 24, 2024 | Tax withholding | −18,250 | $0.47 | $8.58K | 93,940 |
| Cuong V. Do President & CEO, Director | Jun 24, 2024 | Tax withholding | −42,000 | $0.47 | $19.74K | 551,948 |
| Cuong V. Do President & CEO, Director | Jun 24, 2024 | Award | +168,000 | – | – | 593,948 |
| Joseph M. Palumbo Chief Medical Officer | Jun 24, 2024 | Award | +116,000 | – | – | 148,196 |
| Joseph M. Palumbo Chief Medical Officer | Jun 24, 2024 | Tax withholding | −29,000 | $0.47 | $13.63K | 119,196 |
| Cuong V. Do President & CEO, Director | Mar 4, 2024 | Buy | +10,000 | – | – | 435,854 |
| Joanne Wendy Kim Chief Financial Officer | Feb 15, 2024 | Tax withholding | −2,476 | $1.18 | $2.92K | 39,196 |
| Cuong V. Do President & CEO, Director | Feb 15, 2024 | Tax withholding | −4,953 | $1.18 | $5.84K | 425,948 |
| Joseph M. Palumbo Chief Medical Officer | Feb 15, 2024 | Tax withholding | −2,476 | $1.18 | $2.92K | 32,196 |
| Joanne Wendy Kim Chief Financial Officer | Dec 11, 2023 | Award | +5,000 | – | – | 44,148 |
| Steve Gorlin Director | Dec 1, 2023 | Sale | −75,680 | $1.69 | $127.90K | 46,358 |
| Cuong V. Do President & CEO, Director | Nov 30, 2023 | Buy | +10,000 | $1.78 | $17.80K | 68,759 |
| Steve Gorlin Director | Nov 9, 2023 | Award | +46,358 | – | – | 122,038 |
| Richard J. Berman Director | Nov 9, 2023 | Award | +51,830 | – | – | 69,235 |
| Robert J. Hariri Director | Nov 9, 2023 | Award | +42,254 | – | – | 42,254 |
| Sigmund Rogich Director | Nov 9, 2023 | Award | +42,254 | – | – | 42,254 |
| Steve Gorlin Director | Sep 5, 2023 | Sale | −8,560 | $3.05 | $26.11K | 75,680 |
| Richard J. Berman Director | Aug 22, 2023 | Sale | −10,805 | $3.50 | $37.82K | 16,789 |
| Cuong V. Do CEO & President, Director | Jun 29, 2023 | Award | +149,500 | – | – | 425,854 |
| Cuong V. Do CEO & President, Director | Jun 21, 2023 | Option exercise | +41,506 | – | – | 271,401 |
| Richard J. Berman Director | Jun 7, 2023 | Sale | −5,984 | $5.81 | $34.77K | 23,210 |
| Richard J. Berman Director | May 22, 2023 | Sale | −5,000 | $6.50 | $32.50K | 29,194 |
| Richard J. Berman Director | Mar 28, 2023 | Sale | −2,613 | $8.52 | $22.26K | 34,194 |
| Richard J. Berman Director | Mar 28, 2023 | Sale | −5,000 | $8.52 | $42.60K | 36,807 |
| Richard J. Berman Director | Mar 27, 2023 | Sale | −3,371 | $8.52 | $28.72K | 41,807 |
| Joanne Wendy Kim Chief Financial Officer | Feb 16, 2023 | Tax withholding | −2,476 | $5.51 | $13.64K | 41,672 |
| Cuong V. Do President & CEO, Director | Feb 16, 2023 | Tax withholding | −4,953 | $5.51 | $27.29K | 430,901 |
| Joseph M. Palumbo Chief Medical Officer | Feb 16, 2023 | Tax withholding | −2,476 | $5.51 | $13.64K | 34,672 |
| Clarence N. Ahlem EVP Neuroscience Product Dev. | Feb 16, 2023 | Tax withholding | −2,476 | $6.12 | $15.15K | 37,148 |
| Penelope Markham EVP Liver Cirrhosis R&D | Feb 16, 2023 | Tax withholding | −2,476 | $6.12 | $15.15K | 47,841 |
| Joseph M. Palumbo Chief Medical Officer | Feb 16, 2023 | Tax withholding | −2,476 | $6.12 | $15.15K | 37,148 |
| Cuong V. Do CEO & President, Director | Feb 16, 2023 | Tax withholding | −4,953 | $6.12 | $30.31K | 229,895 |
| Christopher Reading EVP Neuroscience R&D | Feb 16, 2023 | Tax withholding | −2,476 | $6.12 | $15.15K | 37,148 |
| Joanne Wendy Kim Chief Financial Officer | Feb 16, 2023 | Tax withholding | −2,476 | $6.12 | $15.15K | 39,148 |
| Joseph M. Palumbo Chief Medical Officer | Nov 23, 2022 | Award | +39,624 | – | – | 39,624 |
| Robert J. Hariri Director | Nov 23, 2022 | Award | +34,240 | – | – | 34,240 |
| Penelope Markham EVP Liver Cirrhosis R&D | Nov 23, 2022 | Award | +39,624 | – | – | 50,317 |
| James Paul Lang Director | Nov 23, 2022 | Award | +43,578 | – | – | 68,622 |
| Clarence N. Ahlem EVP Neuroscience Product Dev. | Nov 23, 2022 | Award | +39,624 | – | – | 39,624 |
| Steve Gorlin Director | Nov 23, 2022 | Award | +34,240 | – | – | 84,240 |
| Richard J. Berman Director | Nov 23, 2022 | Award | +43,578 | – | – | 45,178 |
| Christopher Reading EVP Neuroscience R&D | Nov 23, 2022 | Award | +39,624 | – | – | 39,624 |
| Joanne Wendy Kim Chief Financial Officer | Nov 23, 2022 | Award | +39,624 | – | – | 41,624 |
| Cuong V. Do CEO & President, Director | Nov 23, 2022 | Award | +79,248 | – | – | 234,848 |
| Terren S. Peizer Director, 10% owner | Aug 15, 2022 | Award | +3,636,364 | $1.65 | $6.00M | 23,166,210 |
| Jonathan M. Adams EVP Liver Cirrhosis Programs | Feb 2, 2022 | Gift | −1,000 | – | – | 48,630 |
| Cuong V. Do President & CEO, Director | Dec 31, 2021 | Award | +21,710 | – | – | 58,759 |
| Joanne Wendy Kim CFO | Dec 7, 2021 | Buy | +2,000 | $5.40 | $10.80K | 2,000 |
| Jonathan M. Adams EVP Liver Cirrhosis Programs | Jun 16, 2021 | Gift | −10,000 | – | – | 49,630 |
| Terren S. Peizer Director, 10% owner | Jun 10, 2021 | Award | +8,361,308 | – | – | 19,529,846 |
| Steve Gorlin Director | Nov 3, 2020 | Buy | +2,430 | $7.95 | $19.32K | 45,100 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of BioVie's stock actually held short. Settlement fails (shares not delivered on time) peaked at 808,725 shares on Aug 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Steve Gorlin Director | Dec 1, 2023 | 25,680 | $43.40K | Dec 1, 2023 | Performance Stock Units |
| Deborah Gorlin Wife of director Steve Gorlin | Dec 1, 2023 | 50,000 | $84.50K | Dec 1, 2023 | Open Market Purchase |
| Steve Gorlin Director | Sep 5, 2023 | 8,560 | $26.11K | Sep 5, 2023 | Performance Stock Units |
See a number that looks wrong?